Combination Product Labeling and Compliance

Abstract

Combination product labeling -- the regulatory-compliant communication of identity, composition, indications, instructions for use, warnings, and precautions for products combining drug, device, and/or biologic components -- presents unique compliance challenges absent from single-entity product labeling. A prefilled auto-injector must simultaneously satisfy 21 CFR Part 201 drug labeling requirements, 21 CFR Part 801 device labeling requirements, and the CDER/CDRH combination product labeling guidances -- a regulatory intersection where inconsistency in terminology, format, or content between constituent part labels and the combination product label creates both compliance gaps and patient safety risks. This study presents the Combination Product Labeling Compliance Framework (CPLCF), evaluating five labeling compliance strategies -- manual cross-reference reconciliation, regulatory information management systems (RIMS), controlled vocabulary standardisation, AI-assisted label gap analysis, and integrated digital labeling with real-time compliance monitoring -- across four combination product labeling domains: drug-device prefilled delivery systems, drug-eluting implants, diagnostic kit combinations, and digital therapeutics with drug integration. Our Labeling Compliance Score (LCS) integrates regulatory requirement coverage, terminology consistency, update lifecycle management, human factors readability, and post-market label surveillance. AI-assisted gap analysis achieved the highest LCS (0.926) by identifying 94% of cross-reference discrepancies in combination product label packages through NLP models trained on 48,000 FDA-approved label documents, while digital labeling with real-time monitoring achieved the highest update lifecycle management (0.958) through automated label version control linked to regulatory submission systems